Biotech lobby groups in Washington push to keep Chinese low-cost drug pipeline open amid rising anti-China proposals

Washington biotech lobby groups are working to ensure a steady flow of affordable medicines that originate from Chinese manufacturers.

These groups have become aware that they are encountering vocal opposition from lawmakers and advocacy groups who are pushing a series of anti-China measures.

The lobbying effort aims to counter those proposals and preserve access to lower-cost drugs for U.S. patients, arguing that the Chinese pipeline remains essential for the industry.